Publications

Inositoli: storia e personaggi di una terapia efficace

La storia dell’inositolo è una storia complessa: nel 1850 Johanes Joseph Scherer isolò dal mu­scolo un esaidrocicloesano a cui diede il nome di inositolo 1 (dal greco inos= muscolo). La struttu­ra del cicloesano permette la formazione di nove diversi stereoisomeri. Tra essi, ii myo-inositolo è l’isomero di gran lunga più distribuito in natura …

More
Infertility / Myo-Inositol

Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. It is characterized by chronic anovulation, hyperandrogenism, and insulin resistance. It is the main cause of infertility due to the menstrual dysfunction and metabolic disorders. Women with PCOS also have an increased cardiovascular risk because of dyslipidemia and …

More
Publications

Myo-inositol ovarian stimulation and IVF outcomes

OBJECTIVE: More than 60% of in vitro fertilization (IVF) cycles do not result in pregnancy. Several studies have been carried out in order to identify factors affecting the IVF outcome. The main factors influencing IVF outcome are oocyte and embryo quality. Indeed, the only way to improve IVF success rate is toimprove oocyte …

More
Infertility / Myo-Inositol

Hereditay hemorragic teleangectasia and pregnancy

We report an uncommon case of a 38-years-old pregnant woman affected by HHT (Hereditary haemorrhagic telangiectasia; OslerWeber-Rendu syndrome) who underwent to a caesarean section (CS) without any complication. The patient at 36th weeks+1 day pregnancy referred to the Emergency Obstetric Unit due to a intercostals pain on left side. On third day after …

More
Publications

Efficacy and safety of 17a-hydroxyprogesterone caproate in hormone replacement therapy

The aim of the present study was to evaluate the efficacy (in terms of induction of uterine bleeding) and safety (in terms of absence of endometrial hyperplasia) of 17a-hydroxyprogesterone caproate (17a-HPC) in a therapeutic regimen for hormonal replacement after menopause. Fifty postmenopausal patients received hormone replacement therapy (HRT) for 24 weeks. The treatment …

More
Infertility / Myo-Inositol

Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use

Objective: Dose-dependent side effects related to myo-inositol (MI) oral administration represent a significant shortcoming for its clinical use. Aiming to search for a pharmaceutical form able to be better absorbed, the pharmacokinetic (PK) profile of the new manufactured MI soft gelatin capsule form was evaluated and compared with the commercially available MI powder.
Research design and methods: A …

More
Infertility / Myo-Inositol

Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use

 

Objective: Dose-dependent side effects related to myo-inositol (MI) oral administration represent a significant shortcoming for its clinical use. Aiming to search for a pharmaceutical form able to be better absorbed, the pharmacokinetic (PK) profile of the new manufactured MI soft gelatin capsule form was evaluated and compared with the commercially available MI powder.

More

Myo-Inositol / Publications

Myo-inositol in the treatment of premenstrual dysphoric disorder

Objective Premenstrual dysphoric disorder (PMDD) is a mood disorder disrupting social and/or occupational life of affected women. Premenstrual dysphoric disorder etiology is unknown, although a pivotal role is played by the serotoninergic system. Indeed, one of the most effective treatments is selective serotonin reuptake inhibitors. Several studies have proposed a selective serotonin reuptake …

More